Telix Pharmaceuticals Limited (ASX:TLX)
Australia · Delayed Price · Currency is AUD | Market Cap | 7.00B |
| Revenue (ttm) | 783.21M |
| Net Income (ttm) | 49.92M |
| Shares Out | 338.38M |
| EPS (ttm) | 0.14 |
| PE Ratio | 143.02 |
| Forward PE | 41.92 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 766,456 |
| Average Volume | 1,754,772 |
| Open | 20.89 |
| Previous Close | 20.68 |
| Day's Range | 20.69 - 21.21 |
| 52-Week Range | 17.03 - 31.97 |
| Beta | 2.39 |
| RSI | 32.51 |
| Earnings Date | Aug 19, 2025 |
About Telix Pharmaceuticals
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney ... [Read more]
Financial Performance
In 2024, Telix Pharmaceuticals's revenue was 783.21 million, an increase of 55.85% compared to the previous year's 502.55 million. Earnings were 49.92 million, an increase of 857.95%.
Financial StatementsNews
Telix H1 2025 Results: Investor Webcast Notification
MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will release its financial results for the...
Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman
SAN FRANCISCO, July 29, 2025 (GLOBE NEWSWIRE) -- On July 23, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares significantly fall after t...
Telix Pharmaceuticals: Assessing The Market's Pullback On SEC Inquiry
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX). Such investors are ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX
NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or the "Company") (NASDAQ: TLX). Such investors are adv...
Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Telix Pharmaceuticals Lim...
Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) investors concerning the C...
INVESTOR ALERT: Investigation of Telix Pharmaceuticals Limited (TLX) Announced by Holzer & Holzer, LLC
ATLANTA, July 23, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) complied with federal securities laws. O...
Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Telix Pharmaceuticals Limited (“Telix” or the “Company”) (NASDAQ: TLX) on behalf of investors concerning th...
Telix Pharmaceuticals stock drops as SEC probes disclosures tied to cancer treatment
Telix Reports $204M Revenue, Up 63% YOY
MELBOURNE, Australia and INDIANAPOLIS, July 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today provides an update on its commercial and operational perfo...
Gozellix Receives Permanent HCPCS Code
MELBOURNE, Australia and INDIANAPOLIS, July 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that its next-generation PSMA1 PET2 imaging agen...
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
MELBOURNE, Australia and INDIANAPOLIS, June 23, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces that the United States (U.S.) Foo...
Telix Precision Medicine Announces AlFluor Radiochemistry Platform
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces it has launched a novel PET1 radi...
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and t...
This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
MELBOURNE, Australia and INDIANAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) provides further details on the agenda for the Co...
Telix Pharmeceuticals: Imaging Biomarkers Paving The Way For Theranostics
Telix Pharmaceuticals excels in radiopharmaceuticals, with strong revenue growth driven by imaging products like Illuccix and promising therapeutic programs in development. TLX's key imaging projects ...
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
MELBOURNE, Australia and INDIANAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its Fibroblast Activation Protein...
Shareholders that Lost Money on Telix Pharmaceuticals Limited (TLX) Should Contact Levi & Korsinsky About Securities Fraud Investigation - TLX
NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX...
ATTENTION Telix Pharmaceuticals Limited Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX...
Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)
NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX...
Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX)
NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX...
TLX STOCK ALERT: Levi & Korsinsky Notifies Telix Pharmaceuticals Limited Investors of an Ongoing Investigation
NEW YORK, NY / ACCESS Newswire / May 1, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:TLX...
TLX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Telix Pharmaceuticals Limited
NEW YORK, NY / ACCESS Newswire / April 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Telix Pharmaceuticals Limited ("Telix Pharmaceuticals Limited") (NASDAQ:...